type 2 diabetes mellitus
3 articles · search the full text for this term
-
GLP-1 Receptor Agonists: A Dual Therapeutic Strategy for the Management of Type 2 Diabetes Mellitus and Obesity
Abstract: For the treatment of obesity and type 2 diabetes mellitus (T2DM), glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a revolutionary class of pharmaceutical drugs. These drugs were first created as glucose-lowering treatments, but they have now shown other advantages, such as notable weight loss, better cardiovascular results, and general metabolic control. The objective of this narrative review is to assess the pharmacological mechanisms, clinical efficacy, safety profile, and therapeutic …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 16, Issue 1, 2026 · pp. 69–75 Read article
-
Role of Inflammatory Markers and Lipid Abnormalities in Glycemic Dysregulation Among Type 2 Diabetics
Abstract: Background: Diabetes mellitus (DM) is a chronic metabolic disorder characterized by systemic inflammation and associated with various complications in multiple organs. Type 2 diabetes mellitus (T2DM) specifically involves insulin resistance, hyperglycemia, and inflammatory responses. This study investigates the levels of various inflammatory markers and their correlation with glycaemic control in T2DM patients. Objective: To evaluate the levels of inflammatory markers (including NLR, PLR, SII, SIRI, CRP, IL-6, TNF-α, TGF-β, MCP-1, …
Published in Emerging Trends in Metabolites · Vol. 2, Issue 2, 2025 Read article
-
Practical approach for Type 2 Diabetes: Role of DPP4 Inhibitors
Abstract: Dipeptidyl peptidase-4 inhibitors (DPP-4Is) have become essential in managing type 2 diabetes mellitus (T2DM) due to their ability to enhance incretin hormone activity, which promotes insulin secretion and inhibits glucagon release. These agents effectively lower HbA1c levels by 0.5–1.0%, are weight-neutral, and have a low risk of hypoglycemia, making them suitable for a broad patient population, including the elderly. The antidiabetic market in India is vast. Gliptin as group row …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 14, Issue 2, 2024 · pp. 20–26 Read article